Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Citterio

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|September 16, 2015
Present and future treatment options for primary CNS lymphomaGiovanni Citterio, Michele Reni, Andrés José Maria Ferreri
Expert Review of Anticancer Therapy|October 25, 2013
Current uses of radiation therapy in patients with primary CNS lymphomaGiovanni Citterio, Andrés José María Ferreri, Michele Reni
Expert Review of Neurotherapeutics|April 11, 2018
Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphomaGiovanni Citterio, Teresa Calimeri, Andrés J M Ferreri
Critical Reviews in Oncology/Hematology|April 22, 2017
Primary central nervous system lymphomaGiovanni Citterio, Michele Reni, Gemma Gatta, et al.
Recenti Progressi in Medicina|June 11, 2013
[The primary mediastinal lymphoma: state of the art and therapeutical perspectives]Marco Foppoli, Giovanni Citterio, Giovanni Donadoni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 13, 2025
Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in CancerSara Fiume, Francesca Molinari, Benedetta Vai, et al.
British Journal of Haematology|October 15, 2014
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab eraAndrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumorsVanesa Gregorc, Filippo G De Braud, Tommaso M De Pas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|September 16, 2015
Present and future treatment options for primary CNS lymphomaGiovanni Citterio, Michele Reni, Andrés José Maria Ferreri
Expert Review of Anticancer Therapy|October 25, 2013
Current uses of radiation therapy in patients with primary CNS lymphomaGiovanni Citterio, Andrés José María Ferreri, Michele Reni
Expert Review of Neurotherapeutics|April 11, 2018
Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphomaGiovanni Citterio, Teresa Calimeri, Andrés J M Ferreri
Critical Reviews in Oncology/Hematology|April 22, 2017
Primary central nervous system lymphomaGiovanni Citterio, Michele Reni, Gemma Gatta, et al.
Recenti Progressi in Medicina|June 11, 2013
[The primary mediastinal lymphoma: state of the art and therapeutical perspectives]Marco Foppoli, Giovanni Citterio, Giovanni Donadoni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 13, 2025
Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in CancerSara Fiume, Francesca Molinari, Benedetta Vai, et al.
British Journal of Haematology|October 15, 2014
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab eraAndrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumorsVanesa Gregorc, Filippo G De Braud, Tommaso M De Pas, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Pageof 2